A Study of Tazemetostat on Safety in Participants With Relapsed or

See also
Status	Clinical Trial	Phase
Completed	`NCT01950273` - Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma	Phase 1
Completed	`NCT00930514` - A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma	Phase 1
Completed	`NCT02472756` - Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma	N/A
Completed	`NCT00193492` - A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma	Phase 2
Withdrawn	`NCT00319332` - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen	Phase 3
Withdrawn	`NCT00092274` - Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma	Phase 1/Phase 2
Completed	`NCT03087929` - Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon	N/A
Terminated	`NCT02413489` - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma	Phase 2
Completed	`NCT00915096` - Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
Recruiting	`NCT05849857` - Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries	Phase 2
Recruiting	`NCT05410418` - Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma	Phase 2
Terminated	`NCT01609036` - An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma	N/A
Completed	`NCT01234766` - Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma	Phase 2
Completed	`NCT00849147` - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)	Phase 2
Terminated	`NCT00384111` - Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL)	Phase 3
Completed	`NCT03682796` - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma	Phase 1
Recruiting	`NCT04982471` - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Active, not recruiting	`NCT02996773` - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine	Phase 1
Terminated	`NCT00562965` - Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)	Phase 3
Active, not recruiting	`NCT00317096` - FCM Versus R-FCM Followed by R-Maintenance or Observation Only	Phase 3

NCT number	NCT05228158
Study type	Observational
Source	Eisai Inc.
Contact	Inquiry Service
Email	eisai-chiken_hotline@hhc.eisai.co.jp
Status	Recruiting
Phase
Start date	August 16, 2021
Completion date	March 31, 2028

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms